Roche’s live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress Replay
Roche has hosted a live audio webcast and conference call on Monday, 22 October 2018.
Agenda:
Welcome
Daniel O’Day, CEO Roche Pharmaceuticals
ESMO 2018 Key CIT readouts across tumor types
- IMpassion130: Tecentriq + Abraxane in 1L triple-negative breast cancer
Jakob Dupont, M.D., Global Head Breast & Gyn Cancer Franchise, Pharma Development
- IMpower130: Tecentriq + Abraxane in 1L non-sq NSCLC
BF1RST: Association between bTMB and Tecentriq efficacy in 1L NSCLC
ALESIA: Alecensa in 1L ALK+ NSCLC in Asian patients
STARTRK2: Entrectinib in NTRK+ solid tumors
GO30140: Tecentriq + Avastin in 1L HCC
Alan Sandler, M.D., Global Head of Lung/Head & Neck Franchise, Pharma Development, a.i. Global Head Oncology
Roche Oncology strategy update
Cynthia Perettie, Head Global Product Strategy Oncology